Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Iressa in Asymptomatic Radio-Naive Brain Metastases from NSCLC
NCT00234442Phase 2Terminated
- Sponsor
- AstraZeneca
- Start
- Jul 2004
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of gefitinib in non-small cell lung cancer (NSCLC) and brain metastases, sponsored by AstraZeneca. Primary endpoint: Disease control rate. Started Jul 2004; status: terminated.
02
Drugs
03
Conditions
non-small cell lung cancer (NSCLC)brain metastases
Beyond the preview
Go deeper on NCT00234442.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00234442.